Bucindolol
Bucindolol is a non-selective beta blocker and beta-1 adrenergic receptor antagonist that was developed to treat hypertension and heart failure. It is unique among beta blockers for its additional properties as a beta-2 adrenergic receptor antagonist and alpha-1 adrenergic receptor antagonist.
Pharmacology[edit | edit source]
Bucindolol is a beta blocker, a class of drugs that work by blocking the action of epinephrine (adrenaline) on the beta receptors in the heart and blood vessels. This slows the heart rate and reduces the force of heart contractions, which lowers blood pressure and reduces the heart's demand for oxygen. Bucindolol is non-selective, meaning it blocks both beta-1 and beta-2 receptors.
In addition to its beta-blocking activity, Bucindolol also has mild vasodilating properties due to its antagonism of alpha-1 adrenergic receptors. This can help to further lower blood pressure.
Clinical Use[edit | edit source]
Bucindolol was developed for the treatment of hypertension (high blood pressure) and heart failure. In heart failure, it works by reducing the heart's workload and helping the heart to pump more efficiently. In hypertension, it helps to lower blood pressure by reducing the force and rate of heart contractions.
Side Effects[edit | edit source]
Like all medications, Bucindolol can cause side effects. Common side effects include bradycardia (slow heart rate), hypotension (low blood pressure), fatigue, and dizziness. Less common side effects can include depression, insomnia, and shortness of breath.
Development and Approval[edit | edit source]
Bucindolol was developed by a pharmaceutical company called Bristol-Myers Squibb. However, it was not approved by the Food and Drug Administration (FDA) in the United States due to concerns about its side effect profile. Despite this, it has been approved for use in other countries.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
